Pre-eclampsia is a serious disorder of human pregnancy, characterized by decreased utero-placental perfusion and increased trophoblast cell death. Presently, the mechanisms regulating trophoblast cell death in pre-eclampsia are not fully elucidated. Herein, we have identified a novel Mtd/Bok splice isoform (Mtd-P) resulting from exon-II skipping. Mtd-P expression was unique to early-onset severe pre-eclamptic placentae as assessed by quantitative real-time-PCR and immunoblotting. Mtd-P overexpression in cell lines (BeWo: cytotrophoblast-derived; and CHO: ovary-derived) resulted in increased apoptotic cell death as assessed by caspase-3 cleavage, internucleosomal DNA laddering and mitochondrial depolarization. Moreover, Mtd-P expression increased under conditions of low oxygenation/oxidative stress in human villous explants. Antisense knockdown of Mtd under conditions of oxidative stress resulted in decreased caspase-3 cleavage. We conclude that under conditions of reduced oxygenation/ oxidative stress, Mtd-P causes trophoblast cell death in preeclampsia and hence may contribute to the molecular events leading to the clinical manifestations of this disease.
Introduction
Pre-eclampsia, a complex and serious disorder of human pregnancy, is presently a leading cause of fetal and maternal morbidity and mortality worldwide, affecting approximately 5-7% of all pregnancies. 1 Clinical diagnosis and symptoms are based on sudden onset of hypertension accompanied by proteinuria and edema. Although, the etiology of this disease remains unclear, it is accepted that the placenta plays a central role in its pathogenesis.
A key histopathologic feature of pre-eclampsia is the shallow trophoblast invasion of the maternal site. Doppler studies have demonstrated that the pre-eclamptic fetomaternal interface experiences an abnormally elevated myometrial vascular resistance and decreased utero-placental perfusion as a result of incomplete trophoblast-mediated remodeling of myometrial spiral arteries, which retain their vasoactive characteristic. 2, 3 In this condition, inadequate placental perfusion leads to oxidative stress, placental hypoxia/ischemia and, in severe cases, infarctions. [4] [5] [6] It is postulated that in pre-eclampsia, excessive placental shedding of syncytiotrophoblast microfragments (STBMs) in the maternal circulation, due to elevated apoptosis, may directly contribute to the initiation of a Th1-type maternal inflammatory response culminating in systemic endothelial cell damage. 4, 7 The renewal of placental syncytium, known to be mediated via apoptosis, is a physiological process observed throughout pregnancy, and is believed to be initiated in the underlying mononucleated progenitor cytotrophoblast (CT) layer. 8 Importantly, trophoblast apoptosis as well as syncytial shedding has been shown to be significantly increased in pre-eclampsia. 9, 10 The exact mechanisms causing these events remain unclear.
Proteins within the Bcl-2 family are important intrinsic regulators of apoptosis in normal development and disease. 11, 12 Placental expression of antiapoptotic molecules Bcl-2 and Mcl-1 has been reported in the syncytium (ST) as well as in CT cells of placentae from normal pregnancies. 8, 13 While some studies have reported that Bcl-2 expression is unchanged in placentae of pregnancies complicated by pre-eclampsia, 14, 15 others have reported a decreased expression of this molecule in severe pre-eclampsia when compared to controls. 16 Both proapoptotic molecules Bax and Bak are expressed in villous CT cells and in syncytium of normal placentae, 13 but their expression is not different between placentae of pre-eclamptic and control subjects. but its human placental expression is unknown. To date, two Mtd splice isoforms have been characterized: Mtd-L, a fulllength proapoptotic protein that primarily interacts with Mcl-1, and Mtd-S, a shorter proapoptotic transcript resulting from fusion of BH3 and BH1 domains. The function of this short isoform cannot be antagonized by any known antiapoptotic Bcl-2 family member. 19 Herein, we have investigated Mtd expression in the human placenta. We report the identification and functional characterization of a novel splice variant of the Mtd gene (Mtd-P) and its expression and significance in normal placental development as well as in placental tissue from pregnancies complicated by pre-eclampsia.
Results

Mtd gene expression in first-trimester placental tissues
The expression of previously characterized transcripts of Mtd (Mtd-L and Mtd-S) was observed in first-trimester tissues (6-12 weeks) ( Figure 1a ). While Mtd-L expression (794 bp) was constant throughout first-trimester samples, Mtd-S expression (665 bp) appeared to decrease in tissues from 10 to 12 weeks when compared to earlier gestations. Importantly, a 546 bp band exhibiting strong Mtd-specific hybridization was observed predominantly around 6-8 weeks. Sequencing of the 546 bp band revealed a novel Mtd transcript referred to in this study as Mtd-P.
Mtd-P is a novel Mtd transcript resulting from exon II skipping
Sequence analysis of Mtd-P transcript showed a 249 bp deletion spanning bp 217-466 in the full-length mRNA (NM_032515). This deletion included part of the 5 0 UTR, the original start methionine, the BH4 and part of the BH3 domain, resulting in a deletion of 83 amino acids (Figure 2a) . The genomic structure of Mtd is composed of five putative exons and four introns localized on chromosome 2q37.3. Mtd-P was noted to undergo exon II skipping (orange box), resulting in deletion of BH4 and part of BH3 domains. The protein product of Mtd-P has a theoretical molecular weight of approximately 15 kDa (Figure 2b ). The putative pore-forming region encoded by exon IV is retained in all isoforms.
Mtd protein expression in first-trimester placental tissues
Next, we examined Mtd protein expression using an antibody generated against a peptide sequence derived between BH2 and BH1 domains of Mtd-L, thus recognizing all known isoforms. Immunoblotting confirmed expression of previously characterized Mtd isoforms (Mtd-L and Mtd-S) in firsttrimester tissues in addition to a novel Mtd-specific band with an apparent molecular weight of 15 kDa, corresponding to the predicted molecular weight of Mtd-P (Figure 1b) . Mtd-S runs at its predicted molecular weight (18 kDa), while Mtd-L (predicted molecular weight: 23 kDa) was observed at an apparent molecular weight of 28 kDa, possibly due to posttranslational modifications (Figure 1b) . While Mtd-L and Mtd-S protein expression was constant across first trimester gestations based on Western blotting and densitometric analyses, Mtd-P was the only isoform whose expression significantly increased around 6-8 weeks when compared to later gestations (2.2-fold increase, P ¼ 0.04) (Figure 1d ). Similar to protein expression, quantitative real-time PCR (qRT-PCR) demonstrated that while Mtd-P transcript expression increased significantly in early first-trimester compared to later gestations (3.4-fold increase, P ¼ 0.03), Mtd-L gene expression was unchanged across first trimester samples ( Figure 1c) .
Next, Mtd spatial localization was assessed by immunohistochemistry. Positive immunoreactivity was mostly observed in early first-trimester sections (6 weeks) and was predominately localized to the progenitor mononucleated CT cells (Figure 1e , left panel). Low/absent Mtd immunoreactivity was noted in the multinucleated syncytiotrophoblast layer (ST). In contrast, tissue sections from later first-trimester gestations (12 weeks) exhibited low/absent Mtd expression in CT cells (right panel), while Mtd-positive immunoreactivity was detected in the apical membrane of the syncytiotrophoblast layer. Stromal regions were Mtd negative. Neighboring control sections (no 11 Ab) were also Mtd negative. Finally, Mtd expression colocalized with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining also predominantly observed in early first trimester compared to later gestations (lower panels).
Mtd expression is elevated in pre-eclampsia
As pre-eclampsia is characterized by increased trophoblast cell death, we next examined whether Mtd expression was altered in placentae complicated by this disease. Mtd gene expression was increased in pre-eclamptic placental tissues particularly with respect to Mtd-P when compared to normotensive age-matched controls (Figure 3a) . Densitometric analyses (RT-PCR followed by Southern blot) revealed that elevated gene expression was only significant with respect to Mtd-L and Mtd-P transcripts in pre-eclamptic samples, but not Mtd-S (Mtd-L: 2.7-fold, P ¼ 0.004; Mtd-S: 1.7-fold (not significant); Mtd-P: 3.5-fold, P ¼ 0.006). qRT-PCR analyses further validated that the expression of Mtd-L and particularly that of Mtd-P increased in pre-eclamptic tissues when compared to preterm age-matched normotensive control patients (Mtd-L: 2.1-fold, P ¼ 0.03; Mtd-P: 3.3-fold, P ¼ 0.01; Figure 3c ). Increased Mtd protein content in early-onset pre-eclampsia was particularly notable with respect to Mtd-P (Figure 3b ). Protein densitometric analysis revealed that Mtd-L and Mtd-P were significantly elevated in pre-eclamptic tissues by approximately 3.6-fold (Po0.05) and 5.1-fold (Po0.05) respectively, when compared to preterm age-matched control tissues (Figure 3d ). Similar to Mtd-S gene expression, the 1.9-fold increase in Mtd-S protein level in pre-eclampsia was not statistically significant when compared to controls (Figure 3d ).
We next compared Mtd protein expression between preeclamptic pregnancies (early and late onset) and normotensive pregnancies affected by intrauterine growth restriction (IUGR), essential hypertension as well as normal term deliveries. We observed that only pre-eclamptic placentae complicated by early severe onset of disease exhibited increased expression of Mtd-L and particularly that of Mtd-P molecule (Figure 3e ). Normal term placentae, IUGR placentae and placentae from pregnancies from essential hypertensive subjects did not show increased Mtd expression.
Interestingly, tissues from later third-trimester patients (35-37 weeks) affected by pre-eclampsia in combination with IUGR showed increased expression of Mtd-L, but not Mtd-P, when compared to control subjects. Additionally, we failed to observe differences in Mtd expression between term (late Immunohistochemical analysis demonstrated strong positive Mtd immunoreactivity in all trophoblast cell layers of earlyonset pre-eclamptic placental tissues when compared to controls ( Figure 4 ). Interestingly, in pre-eclamptic tissues, increased Mtd expression was localized to syncytial knots (SK), demonstrating the potential involvement of this molecule in increased trophoblast cell death leading to increased shedding of STBMs in pre-eclampsia (lower right panel). In contrast, low/absent Mtd expression was observed in placental sections of normotensive age-matched controls (upper panels). TUNEL analysis demonstrated a notable increase in apoptotic cell death in the placental trophoblast cell layers of pre-eclamptic tissues when compared to age-matched control samples.
Mtd-P is a pro-apoptotic molecule exerting its function through the mitochondrial pathway
The apoptotic function of Mtd-P was next assessed. (Figure 6i ). In contrast, Mtd-L and Mtd-S protein expressions remained unchanged between 3 and 20% oxygen (Figure 6i) . Additionally, as hypoxia/ reoxygenation was recently demonstrated to be a potent inducer of trophoblast cell death, 20 we tested whether Mtd expression was altered under such conditions. The transcript expressions of Mtd-L (three-fold, P ¼ 0.0007) and Mtd-P (1.6-fold, Po0.05) were significantly increased under H/R conditions when compared to standard conditions (Figure 6h) .
Similarly, Mtd-L and Mtd-P protein expressions were also observed to increase in HR conditions relative to standard conditions (Figure 6i ). In summary, these data collectively demonstrate a direct correlative expression between the transcript and protein levels of Mtd isoforms in various oxygenation conditions.
To assess whether Mtd has a direct involvement in trophoblast cell death, we next tested the effect of Mtd knockdown, using a previously validated antisense (AS) approach, 21 in human villous explants and monitored for signs of apoptosis. We assessed the effect of AS isoformspecific oligonucleotide treatment (AS-L and AS-P) under conditions of oxidative stress (HR), as this condition was shown to be the strongest inducer of Mtd isoforms. To confirm the success of Mtd transcript knockdown, Mtd-L and Mtd-P expressions were measured using qRT-PCR in control Sand AS-treated conditions relative to untreated tissues (C). As previously observed, HR conditions significantly increased Mtd-L and Mtd-P transcript levels relative to control conditions (Figure 6j ). Furthermore, AS-Mtd-L and AS-Mtd-P treatments significantly decreased their expression levels by 68 and 67%, respectively, when compared to control S-treated conditions ( Figure 6j ). As cleaved caspase-3 expression has previously been demonstrated to be a reliable marker to trophoblast apoptosis, 20 we assessed its expression by immunoblotting in explants treated with AS-Mtd (L and P) as well as control conditions (S-Mtd-L/P and no oligos: C). AS treatment resulted in markedly reduced cleavage of caspase-3 relative to control conditions, demonstrating decreased levels of apoptosis (Figure 6k ).
Discussion
This study reports the placental expression of two previously characterized Mtd isoforms (Mtd-L and Mtd-S) and most importantly the identification and characterization of Mtd-P, a novel Mtd splice variant resulting from exon II skipping. Our data demonstrate that (1) Mtd-P has a distinctive developmental expression profile, (2) Mtd-P overexpression is unique to pregnancies complicated by severe early-onset pre-eclampsia, (3) Mtd-P is a proapoptotic molecule involved in trophoblast cell death and (4) Mtd-P expression is increased under conditions of reduced oxygenation and oxidative stress.
Interaction between pro-and antiapoptotic Bcl-2 family members is critical in the physiologic fine-tuning of apoptosis. 11 The proapoptotic activity of the widely expressed Bax and Bak molecules is countered by their ability to interact with various antiapoptotic Bcl-2 family members, including Bcl-2, Bcl-w and Bcl-xL. 11 This contrasts the interaction capability of Mtd-L, which essentially heterodimerizes with the antiapoptotic Mcl-1 molecule. 17, 19 Interestingly, Mtd-S, resulting from fusion of BH3 and BH1 domains, lacks the ability to interact with any presently known antiapoptotic Bcl-2 family members. 19 Mtd-P identified herein is missing 15 of the 18 amino acids that compose the BH3 domain. Mutation of key residues in the BH3 domain of Mtd-L as well as artificial fusion of BH3 and BH1 domains in Bax and Bak has no effect on the killing ability of these molecules. 19 As well, site-directed mutagenesis of conserved BH3 residues LLRLGDEL to either glycine or alanine in Mtd-L abolishes the heteromerization properties of this protein with Mcl-1, but does not impede its killing ability. 19 BH3 residues mutated in Mtd-L are not present in the open reading frame of Mtd-P, suggesting that this molecule may induce apoptosis irrespective of its interaction with Mcl-1. It should also be noted that the start methionine in Mtd-P corresponds to a glutamine residue in rat and murine protein sequences, and to a tyrosine or arginine in chicken and Drosophila sequences, respectively, 22 demonstrating the species specificity of Mtd-P.
Mitochondrial depolarization in Mtd-P-transfected cells revealed important insights into its killing mechanism. The BH3 domain in the multidomain subfamily of proapoptotic molecules (Bok/Mtd, Bax and Bak) seems irrelevant for killing, but rather the pore-forming region consisting of the a5 and a6 helixes between the BH2 and BH1 domains and to a lesser extent the transmembrane domain appear essential for inducing cell death via mitochondrial membrane destabilization. In support of this argument, a mutant Mtd protein lacking the BH1, BH2 and COOH-terminal hydrophobic tail domain was unable to induce apoptosis. 18 Additionally, an artificially truncated version of Mtd-L only encompassing the BH4 and BH3 domains was also incapable of inducing cell death. 22 Moreover, a recently identified chicken isoform of Mtd (MtdDTM) lacking the transmembrane domain was also found to adversely affect mitochondrial function and sensitize transfected lymphoma-derived cells to apoptotic stimuli, 23 once again stressing the importance of the pore-forming region in inducing cell death. Increased Mtd-P expression in pre-eclampsia may be causative for increased trophoblast cell death and shedding observed in this disease. 7, 9, [14] [15] [16] 24, 25 Our data are, to our knowledge, the first evidence of an expressional difference of a proapoptotic Bcl-2 family member in placentae of preeclamptic versus age-matched control subjects. Previous studies have demonstrated expressional differences of other apoptotic-related molecules in pre-eclamptic and control subjects including elevated expression of serum Fas and elevated placental expression of FasL and p53 in preeclamptic placentae. 15, 26 Of clinical importance, Mtd-P increased expression in pre-eclamptic tissues appears unique to the early severe onset form of pre-eclampsia, as tissues obtained from normotensive age-matched and term control subjects as well as term pre-eclampsia, IUGR and essential hypertensive subjects do not exhibit elevated Mtd-P expression. This may hence be a distinctive feature of placentae from patients suffering from severe early-onset pre-eclampsia.
Our findings of increased Mtd expression in vivo at 5-8 weeks of gestation, when placental pO 2 is low, and in vitro, in villous explants kept at 3% O 2 , are consistent with the idea of oxygen regulating placental Mtd expression and increased apoptosis during early first-trimester placentation. Previous studies including our own have demonstrated that reduced oxygenation in vitro leads to increased levels of trophoblast proliferation. [27] [28] [29] Therefore, it is plausible that mechanisms regulating trophoblast apoptosis and proliferation may be tightly intertwined and as such may both be affected by oxygen. Interestingly, Bcl-W, a prosurvival factor, was recently demonstrated to be involved the regulation of cell cycle progression in spermatogenesis. 30 Bcl-xL/S and Bcl-2 have also been shown to enhance the potential for cellular differentiation by delaying entry into cell cycle. [31] [32] [33] [34] Studies from others have also linked Bag-1, an antiapoptotic molecule that interacts with Bcl-2 and a 70 kDa heat shock protein, to a number of cellular processes besides apoptosis, including cell signaling, proliferation, transcription and cell motility. 30, 35 Altogether, these findings are indicative that members of the Bcl-2 family may play a central role in the regulation of global cellular processes other than apoptosis, possibly via as yet undiscovered pathways involved in cell fate decisions. The exact role of Mtd-P in regulating CT cell differentiation under conditions of reduced oxygenation remains to be elucidated.
What is particularly important in our findings is the increased expression of Mtd under conditions of low oxygen and hypoxia-reoxygenation. Previous studies have demonstrated that under hypoxia, primary CT cells, particularly populations isolated from pre-eclamptic placentae, exhibit increased levels of apoptosis. 25, 36 Importantly, reduced uter-oplacental oxygenation and hypoxia-reoxygenation, a direct cause of oxidative stress as it may be the case in early severe onset pre-eclampsia, are potent inducers of villous trophoblast cell death. 20 Our data herein corroborate these findings. Using AS knockdown, we demonstrated that Mtd is a direct regulator of trophoblast cell death under conditions of oxidative stress. Moreover, we have shown that increased expression of Mtd-P as well as Mtd-L in trophoblast cells results in increased apoptotic cell death as measured by caspase-3 cleavage and internucleosomal DNA fragmentation.
Since several putative hypoxia-responsive elements are present in the human Mtd promoter region, it is hence plausible that Mtd expression is under HIF-1 (a transcriptional regulator of oxygen-responsive genes) control. Studies including our own have demonstrated that HIF-1a, the oxygen labile moiety of HIF-1, is elevated in pre-eclamptic placentae. 37, 38 Recent studies have demonstrated that expression of other proapoptotic Bcl-2 family members (Nix and Nip3) is directly regulated by HIF-1a under conditions of reduced oxygenation. 39, 40 Interestingly, hypoxia has also been shown to increase the expression of the proapoptotic Bax and decrease the expression of the antiapoptotic Bcl-2 molecule in human trophoblast cells. 36 Similar to what we demonstrated here, these studies are supporting evidence that oxygen plays a key role in regulating the expression of molecules within the Bcl-2 family and highlight the importance of the mitochondrial pathway in regulating low-oxygen-induced apoptosis. Whether increased Mtd expression in low pO 2 /oxidative stress is directly regulated by HIF-1a or potentially other hypoxia-induced transcription factors such as NF-kB and AP-1 remains to be established. Finally, we should point out that increased Mtd expression in pre-eclampsia may also be p53-dependent, as this transcription factor (a known regulator of Mtd) is increased in hypoxic/oxidative stress conditions as well as in pre-eclampsia and IUGR. 15, 16, 36, 41, 42 Figure 7 Putative model: Mtd role in normal and pre-eclamptic placentae. In pre-eclampsia, alteration in placental oxygenation, due to low pO 2 or oxidative stress (HR), may be responsible for the aberrant expression of Mtd-P, which in turn leads to a change in the physiological apoptotic rheostat in trophoblast cells. This imbalance results in accelerated syncytiotrophoblast cell death resulting in increased shedding of trophoblast microfragments in the maternal circulation Based on our putative model (Figure 7) , we postulate that Mtd overexpression in pre-eclampsia, following reduced oxygenation and/or oxidative stress, shifts the intrinsic trophoblast apoptotic rheostat toward a death pathway and results in increased release of trophoblast microfragments in the maternal circulation. We conclude that Mtd-P is a novel molecule that may be responsible for the molecular events leading to the clinical manifestations of this devastating disorder of pregnancy.
Materials and Methods
Tissue collection
Collection was in accordance with the participating institutions' ethics guidelines. First-trimester human placental tissues (5-13 weeks of gestation, n ¼ 30) were obtained from elective terminations of pregnancies by dilatation and curettage. Pre-eclamptic group was selected based on ACOG clinical and pathological criteria. 43 Calcified, necrotic and visually ischemic areas were omitted from sampling. Patients with diabetes, infections and kidney disease were excluded. Pregnant patients with essential hypertension (EH; n ¼ 4, at term) and pregnancies affected by IUGR (n ¼ 6, gestational age 32-36 weeks with fetal weight less than 5th percentile) without pre-eclampsia were included as controls. Preterm control patients did not show signs of pre-eclampsia or other placental disease. Preterm deliveries were due to multiple pregnancy (27%), preterm labor due to incompetent cervix (41%), premature preterm rupture of membrane (18%) and spontaneous rupture of membranes (14%). Clinical data are summarized in Table 1 .
Human chorionic villous explant culture
Explant cultures were performed as previously described. 27 Explants were maintained in standard condition (5% CO 2 in 95% air) or in an atmosphere of 3% O 2 /92% N 2 /5% CO 2 for 48 h at 371C. In separate experiments, hypoxia/reoxygenation was performed as previously described 20 RT-PCR products were analyzed by Southern blotting using Mtd and b-actin cDNAs labeled with [a-32 P]dCTP (PerkinElmer Life Sciences), using a random hexamer approach. Quantitative PCR was performed using the SYBR Green I dye DyNamot HS kit (MJ Research) based on the manufacturer's protocol using isoform-specific primers (Mtd-L: forward 5 0 -GCCTGGCTGAGGTGTGC-3 0 , Mtd-P: forward 5 0 -GCGGGAGAGGC GATGA, reverse (both L and P) 5 0 -TGCAGAGAAGATGTGGCCA-3 0 ). Analysis was carried out using the DNA Engine Opticon s 2 System (MJ Research). Data were normalized against expression of 18S ribosomal RNA as previously described. 44 Mtd knockdown was performed in villous explants using phosphorothioated (all positions) S and AS oligos designed against Mtd transcript NM_032515 at a final concentration of 10 mM (S-L:
Western blot analysis
Western blot analyses were performed as previously described. 45 Primary antibody (1 : 1000) used was rabbit polyclonal Mtd antibody (generous gift of Dr. J Tilly), 46 or cleaved caspase-3 rabbit polyclonal antibody (Cell Signaling). For Mtd antibody, preimmune serum was used as control. Secondary antibody (1 : 5000) was horseradish peroxidase-conjugated anti-rabbit (Santa Cruz Biotechnology). All immunoblots were checked for equivalent protein loading using ponceau staining.
Immunohistochemistry
Immunohistochemical analyses were performed as previously described. 27, 45 Primary antibody was rabbit polyclonal anti-Mtd (1 : 200) or mouse monoclonal anti-ssDNA (1 : 500), the latter used based on the manufacturer's protocol (MAB3299, Chemicon). Secondary antibody (1 : 400) was biotinylated goat anti-rabbit or goat anti-mouse IgG (Vector Laboratories). 
TUNEL
The in situ Cell Death Detection kit (Roche Molecular Biochemicals) was used based on the manufacturer's protocol.
Plasmid construction
Open reading frames (ORF) of Mtd-L and Mtd-P were directional cloned in pcDNA3.1/Hygro( þ ) (Invitrogen). Forward and reverse primers used encoded a KpnI and a BamHI restriction site, respectively. The Primers were as follows: Mtd-P: forward 5 0 -CCCGGTACCACCATGATCCGGC CCAGCGTCTAC-3 0 , reverse 5 0 -CCCGGATCCGGGTCATCTCTCTGGCA GCAGCAC-3 0 ; Mtd-L: forward 5 0 -CCCGGTACCACCATGATCCGGCCCA GCGTCTAC-3 0 , reverse 5 0 -CCCGGATCCGGGTCATCTCTCTGGCAACA ACAGGAA-3 0 .
Transfection studies
Cell culture (CHO and BeWo; ATCC), transfection, fixation and b-gal staining were performed as previously described. 17 BeWo cells were cultured based on the manufacturer's protocol (ATCC). Transfection was performed with 1.5 mg of construct per 35-mm plate (empty pcDNA3.1/ Hygro( þ ), Mtd-P or Mtd-L in pcDNA3.1/Hygro( þ ) plasmid) using lipofectamine reagent (Invitrogen) in combination with 0.1 mg fraction of pcDNA3.1/Hygro( þ ) encoding the lacZ gene based on the manufacturer's recommendations.
DNA laddering
Genomic DNA was extracted 24 h post-transfection as previously described. 47 Samples were separated on 2% (wt/vol) agarose gel containing 0.5 mg/ml ethidium bromide for 2 h at 40 V and visualized using a UV transluminator.
Mitochondrial membrane potential analysis
Membrane potential was assessed by JC-1 (3 mg/ml working concentration; Molecular Probes) staining based on the manufacturer's protocol for staining in culture dish and FACS analysis. Images were captured using an inverted fluorescent microscope (Leica DMIRB) equipped with fluorescein and rhodamine filters. Stained CHO cells (live cells, dead cells (floating fraction of serum-starved cells) and transfected conditions) were subjected to FACS analysis on an EPICS Elite (Beckman-Coulter) using green (JC-1 monomers) and red (JC-1 aggregates) fluorescence signals resolved by detection in conventional FL1 and FL2 channels, respectively.
Statistical analysis
Data are represented as mean7S.E.M. of at least three separate experiments carried out in triplicate. Statistical difference was determined by Student's t-test for paired groups, significance defined as Po0.05.
